Recursion Pharmaceuticals, Inc. Class A Common Stock RXRX

Recursion Pharmaceuticals, Inc. es una empresa de biotecnología TechBio en etapa clínica. Está enfocada en utilizar tecnologías avanzadas en biología, química, automatización e informática para descubrir y diseñar terapéuticas. La plataforma de la empresa, Recursion Operating System (OS), está construida con diversas tecnologías y permite a la empresa mapear y navegar billones de relaciones biológicas y químicas dentro del Universo de Datos de Recursion. Integra componentes físicos y digitales como bucles iterativos de átomos y bits de datos de biología y química de laboratorio húmedo organizados en ciclos virtuosos con herramientas computacionales para traducir rápidamente hipótesis in silico en ideas validadas y química novedosa. Sus programas clínicos incluyen REC-994, REC-2282, REC-4881 y REC-3964. REC-994 es una molécula pequeña oralmente biodisponible, captadora de superóxido, que se está desarrollando para el tratamiento de la malformación cavernosa cerebral (CCM). REC-2282 se está desarrollando para el tratamiento de la neurofibromatosis tipo 2.

• GlobeNewswire Inc. 7 sept

  AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider

  The global AI in pharmaceutical market is projected to grow from USD 3.07 billion in 2025 to USD 48.43 billion by 2035, with a CAGR of 31.76%. The U.S. market is expected to reach USD 15.10 billion and Europe USD 12.60 billion by 2035. Growth is driven by generative AI, adaptive trials reducing patient enrollment by 40%, regulatory endorsement including FDA's qualification of AIM-NASH, and increased venture capital investment in AI-first drug discovery platforms.

  

• GlobeNewswire Inc. 7 sept

  Drug Repurposing Market to Reach USD 50.91 Billion by 2035, Expanding at 3.93% CAGR | SNS Insider

  The global drug repurposing market is projected to grow from USD 34.79 billion in 2025 to USD 50.91 billion by 2035 at a CAGR of 3.93%. North America leads with 39% market share, while Asia-Pacific shows the fastest growth at 5.02% CAGR. Small molecules dominate at 67% market share, with oncology and neurology as primary therapeutic areas. AI and machine learning are accelerating drug discovery, though intellectual property rights remain a key barrier.

  

• GlobeNewswire Inc. 3 sept

  The Market Just Told You Which Layer Of AI Biology It Is Paying For

  Recent earnings in life sciences technology reveal that the market is rewarding companies with proprietary data and systems of record over those selling software or AI models alone. Veeva Systems beat expectations with strong AI product adoption, while Certara missed on modest software growth and Recursion Pharmaceuticals fell short on revenue expectations. MindWalk Holdings, which owns curated biological data infrastructure, is positioned to benefit from this trend with its HYFT Technology and newly launched ReefIQ platform, though it remains unprofitable with modest recurring revenue.

  

• GlobeNewswire Inc. 25 ago

  AI Poised to Reshape Blood Cancer Therapeutics as Investment Surges Past $2 Billion Across Leading Biotech and Pharma Players

  Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

  

• GlobeNewswire Inc. 6 ago

  AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine

  Artificial intelligence is fundamentally restructuring bioinformatics, compressing drug discovery timelines and attracting billions in venture capital. AI tools like AlphaFold and generative biology platforms are delivering measurable ROI, with companies achieving 99% cost reductions in drug discovery. North America leads adoption, supported by federal programs and substantial R&D investments from established life sciences players.